Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ralph Weissleder
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
T2 Biosystems
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Weissleder is a co-founder of T2 Biosystems. The company is developing next-generation medical diagnostic products using its proprietary technology, combining nanotechnology and miniaturized magnetic resonance (MR) technology to provide rapid, accurate and portable diagnostics. This research grant is focused on developing focused and validating diagnostic MR (DMR) techniques for measuring microvesicle number and composition in whole blood and could potentially enhance the value of T2 Biosystems technology. The Co-Chairs of Partners HealthCare Conflicts of Interest Committee evaluated the financial interest in connection with this research and determined that, based on the nature of the financial interest and the close connection between the company's interests and the research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
MAGNETIC NANOSENSORS FOR BIOMEDICAL ANALYSES OF MICROVESICLES
We propose to develop a new, nanotechnology-based platform for highly sensitive medical diagnosis. The research is highly synergistic, integrating advantages of magnetic nanomaterials, novel bioconjugation chemistry technology, and microelectronics. The developed platform will be applied to detect and screen microvesicles in blood, an emergent diagnostic biomarker in vascular diseases and transfusion medicine.
Filed on June 21, 2013.
Tell us what you know about Ralph Weissleder's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Ralph Weissleder”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Ralph Weissleder | Massachusetts General Hospital | Conflict of Interest | T2 Biosystems | $5,000 - $9,999 |
| Ralph Weissleder | Massachusetts General Hospital | Conflict of Interest | Lumicell | $10,000 - $19,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.